Spark gets FDA's first in vivo gene therapy approval

In its first approval of an in vivo gene therapy, FDA approved Luxturna voretigene neparvovec from Spark Therapeutics Inc. (NASDAQ:ONCE) to

Read the full 214 word article

User Sign In